Results 271 to 280 of about 10,628,173 (384)

Motor Coordination Disorders in Patients with Chronic Kidney Disease. [PDF]

open access: yesJ Clin Med
Jerzak P   +9 more
europepmc   +1 more source

The Case for Early Identification and Intervention of Chronic Kidney Disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

open access: yesKidney International, 2020
M. Shlipak   +51 more
semanticscholar   +1 more source

Correlation Between Fecal Microbiota and Corticosteroid Responsiveness in Primary Immune Thrombocytopenia: an Exploratory Study

open access: yesAdvanced Science, EarlyView.
This study uses gut microbiome data to predict corticosteroid response in patients with immune thrombocytopenia (ITP). Fecal samples from 212 patients with ITP are sequenced. Six machine‐learning algorithms are used to train predictive models. The support vector machine‐based model integrated clinical data and selected microbial species, diversities ...
Feng‐Qi Liu   +38 more
wiley   +1 more source

CircRNA‐mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c‐Myc Axis

open access: yesAdvanced Science, EarlyView.
This study verifies that circRNA‐mTOR exhibits high expression levels in HCC and has a strong correlation with patient prognosis. Mechanistically, circRNA‐mTOR achieves this effect by facilitating the nuclear translocation of RNA‐binding protein (RBP) PSIP1 through specific binding.
Yongchang Tang   +12 more
wiley   +1 more source

Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

open access: yesKidney International, 2020
M. Ostermann   +14 more
semanticscholar   +1 more source

Antigen‐Targeting Inserted Nanomicelles Guide Pre‐Existing Immunity to Kill Head and Neck Cancer

open access: yesAdvanced Science, EarlyView.
This study introduces a tumor‐targeted nanomicelle platform (preS1‐pHLIP) that exploits pre‐existing antiviral immunity to combat heterogeneous cancers. By delivering viral antigens to label tumors as virus‐like targets, the nanomicelles activate antiviral B and T cells, triggering in situ tumor lysis.
Lizhuo Zhang   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy